Esmolol

Generic Name: Esmolol

Brand Names: Brevibloc

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₅NO_₄

CAS Number: 81147-92-4

Unique Ingredient Identifier: MDY902UXSR

Background: Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions. Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine.

The FDA withdrew its approval for the use of all parenteral dosage form drug products containing esmolol hydrochloride that supply 250 milligrams/milliliter of concentrated esmolol per 10-milliliter ampule. Other esmolol formulations are still available for use.

Indication: For the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Also used in noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention.

Associated Conditions: Hypertension, Tachycardia, Abnormal ventricular rate, Heart rate abnormal

Clinical Trials

The Effect of Esmolol on Patients With Sepsis

Not Applicable

Conditions: Sepsis

Interventions: Drug: Placebo
Drug: Esmolol

First Posted Date: 2020-09-03

Last Posted Date: 2020-09-03

Lead Sponsor: Shanghai Zhongshan Hospital

Target Recruit Count: 120

Registration Number: NCT04537767

Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain

Phase 2

Terminated

Conditions: Injection Site Irritation
Pain

Interventions: Drug: Lidocaine
Drug: Esmolol
Other: Placebo

First Posted Date: 2020-04-22

Last Posted Date: 2024-03-29

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 33

Registration Number: NCT04356352

Locations: 🇺🇸
Wake Forest Health Sciences, Winston-Salem, North Carolina, United States

Outcome of Esmolol Potassium Cardioplegia Compared to Potassium Cardioplegia in Patients With Solitary Valvular Disease; Randomized Controlled Study

Not Applicable

Conditions: Cardioplegia Solution Adverse Reaction

Interventions: Drug: Potassium Cardioplegic Solution
Drug: Esmolol

First Posted Date: 2020-03-13

Last Posted Date: 2020-03-13

Lead Sponsor: Kasr El Aini Hospital

Target Recruit Count: 80

Registration Number: NCT04306913

Locations: 🇪🇬
Kasr alainy medical school, Cairo, Egypt

The Effects of Esmolol on the Hemodynamic Response to Orotracheal Extubation

Phase 4

Conditions: Beta Blocker
Hemodynamic Instability

Interventions: Drug: Prophylactic esmolol
Drug: Placebo

First Posted Date: 2020-02-11

Last Posted Date: 2020-02-11

Lead Sponsor: Hospital de Base

Target Recruit Count: 80

Registration Number: NCT04264286

Locations: 🇧🇷
Hospital de Base do Distrito Federal, Brasília, DF, Brazil

Lidocaine Versus Esmolol for Optimizing Surgical Field Visibility

Phase 2

Completed

Conditions: Lumbar Disc Herniation

Interventions: Drug: Lidocaine
Drug: Esmolol

First Posted Date: 2020-02-07

Last Posted Date: 2020-07-02

Lead Sponsor: Zagazig University

Target Recruit Count: 70

Registration Number: NCT04260685

Locations: 🇪🇬
Faculty of Medicine, Zagazig, Elsharkia, Egypt

Age Comparisons of Exercising Muscle O2 Supply in Healthy Adults: Effects of Esmolol Infusion

Early Phase 1

Completed

Conditions: Aging

Interventions: Drug: Saline infusion
Drug: Esmolol infusion
Other: Pre exercise baseline
Other: Isometric handgrip exercise
Other: Semi-recumbent cycling

First Posted Date: 2019-11-29

Last Posted Date: 2025-05-13

Lead Sponsor: David N. Proctor, PhD

Target Recruit Count: 30

Registration Number: NCT04181606

Locations: 🇺🇸
Noll Laboratory, University Park, Pennsylvania, United States

Role of Intraoperative Beta Blocker for Morbid Obese Patients Undergoing Laparoscopic Bariatric Surgery

Phase 4

Conditions: Postoperative Pain
Intraoperative Awareness

Interventions: Drug: Esmolol

First Posted Date: 2019-09-12

Last Posted Date: 2019-11-25

Lead Sponsor: Ain Shams University

Target Recruit Count: 60

Registration Number: NCT04086940

Locations: 🇪🇬
Ramymahrose, Cairo, Egypt

Phase 3 Study to Evaluate the Safety and Efficacy of Galnobax® in Treating Diabetic Foot Ulcers

Phase 3

Completed

Conditions: Diabetic Foot Ulcer

Interventions: Drug: Esmolol Hydrochloride
Other: Only Standard of Care
Other: Vehicle Gel

First Posted Date: 2019-06-26

Last Posted Date: 2023-09-22

Lead Sponsor: Novalead Pharma Private Limited

Target Recruit Count: 176

Registration Number: NCT03998436

Locations: 🇮🇳
Deenanath Mangeshkar Hospital and Research Center, Pune, Maharashtra, India
🇮🇳
M.S. Ramaiah Medical College and Hospital, Bangalore, Karnataka, India
🇮🇳
Sapthagiri Institute of Medical Sciences and Research Centre, Bangalore, Karnataka, India

and more 11 locations